Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: Treatment outcomes and a prognostic model to predict survival

Eun Joo Kang, Seock Ah Im, Do Youn Oh, Sae Won Han, Jin Soo Kim, In Sil Choi, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Tae You Kim, Jong Seok Lee, Yung Jue Bang, Keun Wook Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Methods: Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (200 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m2 bolus, followed by 600 mg/m 2 in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (400 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m 2 bolus, followed by 2400 mg/m2 in a 46-h continuous infusion) on day 1. Results: A total of 158 patients were included. The overall response rate was 9.6 % in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 % confidence interval (CI), 1.7-2.5] and 5.6 months (95 % CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 %). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. Conclusions: The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy.

Original languageEnglish
Pages (from-to)581-589
Number of pages9
JournalGastric Cancer
Volume16
Issue number4
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

irinotecan
Leucovorin
Platinum
Fluorouracil
Stomach Neoplasms
Drug Therapy
Survival
Disease-Free Survival
Confidence Intervals
Combination Drug Therapy
Safety
taxane
Therapeutics

Keywords

  • FOLFIRI
  • Gastric cancer
  • Irinotecan
  • Prognostic factor
  • Third-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer : Treatment outcomes and a prognostic model to predict survival. / Kang, Eun Joo; Im, Seock Ah; Oh, Do Youn; Han, Sae Won; Kim, Jin Soo; Choi, In Sil; Kim, Jin Won; Kim, Yu Jung; Kim, Jee Hyun; Kim, Tae You; Lee, Jong Seok; Bang, Yung Jue; Lee, Keun Wook.

In: Gastric Cancer, Vol. 16, No. 4, 01.10.2013, p. 581-589.

Research output: Contribution to journalArticle

Kang, Eun Joo ; Im, Seock Ah ; Oh, Do Youn ; Han, Sae Won ; Kim, Jin Soo ; Choi, In Sil ; Kim, Jin Won ; Kim, Yu Jung ; Kim, Jee Hyun ; Kim, Tae You ; Lee, Jong Seok ; Bang, Yung Jue ; Lee, Keun Wook. / Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer : Treatment outcomes and a prognostic model to predict survival. In: Gastric Cancer. 2013 ; Vol. 16, No. 4. pp. 581-589.
@article{ca40f9309bfc4e6586722b1b629e8b91,
title = "Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: Treatment outcomes and a prognostic model to predict survival",
abstract = "Background: The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Methods: Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (200 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m2 bolus, followed by 600 mg/m 2 in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (400 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m 2 bolus, followed by 2400 mg/m2 in a 46-h continuous infusion) on day 1. Results: A total of 158 patients were included. The overall response rate was 9.6 {\%} in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 {\%} confidence interval (CI), 1.7-2.5] and 5.6 months (95 {\%} CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 {\%}). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. Conclusions: The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy.",
keywords = "FOLFIRI, Gastric cancer, Irinotecan, Prognostic factor, Third-line chemotherapy",
author = "Kang, {Eun Joo} and Im, {Seock Ah} and Oh, {Do Youn} and Han, {Sae Won} and Kim, {Jin Soo} and Choi, {In Sil} and Kim, {Jin Won} and Kim, {Yu Jung} and Kim, {Jee Hyun} and Kim, {Tae You} and Lee, {Jong Seok} and Bang, {Yung Jue} and Lee, {Keun Wook}",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s10120-012-0227-5",
language = "English",
volume = "16",
pages = "581--589",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer

T2 - Treatment outcomes and a prognostic model to predict survival

AU - Kang, Eun Joo

AU - Im, Seock Ah

AU - Oh, Do Youn

AU - Han, Sae Won

AU - Kim, Jin Soo

AU - Choi, In Sil

AU - Kim, Jin Won

AU - Kim, Yu Jung

AU - Kim, Jee Hyun

AU - Kim, Tae You

AU - Lee, Jong Seok

AU - Bang, Yung Jue

AU - Lee, Keun Wook

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Methods: Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (200 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m2 bolus, followed by 600 mg/m 2 in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (400 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m 2 bolus, followed by 2400 mg/m2 in a 46-h continuous infusion) on day 1. Results: A total of 158 patients were included. The overall response rate was 9.6 % in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 % confidence interval (CI), 1.7-2.5] and 5.6 months (95 % CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 %). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. Conclusions: The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy.

AB - Background: The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Methods: Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (200 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m2 bolus, followed by 600 mg/m 2 in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m2 in a 2-h infusion) on day 1, and then leucovorin (400 mg/m2 in a 2-h infusion) and 5-FU (a 400 mg/m 2 bolus, followed by 2400 mg/m2 in a 46-h continuous infusion) on day 1. Results: A total of 158 patients were included. The overall response rate was 9.6 % in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 % confidence interval (CI), 1.7-2.5] and 5.6 months (95 % CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 %). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. Conclusions: The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy.

KW - FOLFIRI

KW - Gastric cancer

KW - Irinotecan

KW - Prognostic factor

KW - Third-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84885961204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885961204&partnerID=8YFLogxK

U2 - 10.1007/s10120-012-0227-5

DO - 10.1007/s10120-012-0227-5

M3 - Article

C2 - 23266882

AN - SCOPUS:84885961204

VL - 16

SP - 581

EP - 589

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 4

ER -